Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Closes Acquisition of Dx QC Shop Blackhawk Biosystems

NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said it has closed its acquisition of Blackhawk Biosystems, a privately held maker of quality-control products for infectious disease testing.
 
Bio-Rad CEO Norman Schwartz said he expects this acquisition will help his company expand its online quality control and inter-laboratory peer group comparison.
 
Financial terms of the acquisition were not disclosed.
 
In the past year Bio-Rad also purchased ProteOptics and made an agreement to acquire Ciphergen’s proteomic tools business, including the company’s SELDI platform.
 
For more on Bio-Rad’s corporate strategy, including its acquisition outlook, read this interview with Bio-Rad vice president Brad Crutchfield conducted by GenomeWeb News sister publication ProteoMonitor

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.